Molecular convergence of neutralizing antibodies in human revealed by repeated rabies vaccination

Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination. Booster vaccination dramatically elevated the neutralizing activity of recalled antibodies, primarily targeting an immunodominant site III epitope with hydrophilic and rugged structures. Strikingly, the majority of site III-directed antibodies in the recall response used a convergent V<sub>H</sub> gene (IGHV3-30), and they exhibited more hydrophilic and shorter paratopes than non-site III antibodies, providing physicochemical advantages for binding to site III. Additionally, several amino acids on heavy chain CDR3 were identified as key sites for acquiring an ultrapotent neutralizing activity through site III binding. Our in-depth analysis of antibody repertoires revealed the molecular signatures of neutralizing antibodies generated by repeated rabies vaccination, possibly as a result of adaptive convergence.

Authors

Institutions

Publication Details

Journal
npj Vaccines
Published
2025-02-23
DOI
https://doi.org/10.1038/s41541-025-01073-5
Citations
4
Primary Topic
Rabies epidemiology and control
Type
article
Field-Weighted Citation Impact
3.11

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Molecular convergence of neutralizing antibodies in human revealed by repeated rabies vaccination

Kohei Yumoto, Taishi Onodera, Naoto Ito, Yoshimasa Takahashi et al.
4 citations
npj Vaccines
Rabies epidemiology and control
3.11
article

Molecular convergence of neutralizing antibodies in human revealed by repeated rabies vaccination

Kohei Yumoto, Taishi Onodera, Naoto Ito, Yoshimasa Takahashi, Tadaki Suzuki, Chidchamai Kewcharoenwong, Hirofumi Sawa, Yukari Itakura, Mizuki Fujisawa, Michihito Sasaki, Arnone Nithichanon, Ganjana Lertmemongkolchai, Daisuke Kuroda, Shinji Takeoka
article en
4 citations

Abstract

Rabies vaccines require repeated immunization to robustly elicit neutralizing antibodies that prevent fatal diseases. Here, we analyzed rabies glycoprotein antibody repertoires at both polyclonal and monoclonal levels following repeated vaccination. Booster vaccination dramatically elevated the neutralizing activity of recalled antibodies, primarily targeting an immunodominant site III epitope with hydrophilic and rugged structures. Strikingly, the majority of site III-directed antibodies in the recall response used a convergent V<sub>H</sub> gene (IGHV3-30), and they exhibited more hydrophilic and shorter paratopes than non-site III antibodies, providing physicochemical advantages for binding to site III. Additionally, several amino acids on heavy chain CDR3 were identified as key sites for acquiring an ultrapotent neutralizing activity through site III binding. Our in-depth analysis of antibody repertoires revealed the molecular signatures of neutralizing antibodies generated by repeated rabies vaccination, possibly as a result of adaptive convergence.

npj VaccinesVol. 10(1)
Waseda University (JP), Health Sciences University of Hokkaido (JP), Khon Kaen University (TH), Hokkaido University (JP), National Institute of Infectious Diseases (JP), Hokkaido University Hospital (JP), Gifu University (JP), Chiang Mai University (TH)
Japan Agency for Medical Research and Development
Good health and well-being
Openalex Percentile: Top 11%
Rabies epidemiology and control
3.11
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.